Location History:
- Gyeonggi-do, KP (2021)
- Seoul, KR (2022 - 2023)
Company Filing History:
Years Active: 2021-2023
Title: Myeong Soo Park: Innovator in Sjogren's Syndrome Treatment
Introduction
Myeong Soo Park is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of medical innovations, particularly in the treatment of Sjogren's syndrome. With a total of 3 patents, his work focuses on developing compositions that can aid in the prevention and treatment of this condition.
Latest Patents
Myeong Soo Park's latest patents include a food composition and a pharmaceutical composition for inhibiting Sjogren's syndrome. Each of these compositions contains C-RAPO (KCTC13986BP) and ATT (KCTC13474BP). These strains have been disclosed to have effects that inhibit sialoadenitis, a symptom of Sjogren's syndrome, and help in maintaining saliva flow rate. The potential applications of these strains extend to food, health food, and pharmaceuticals, making them valuable in the medical field.
Career Highlights
Myeong Soo Park is currently associated with Bifido Co., Ltd., where he continues to innovate and develop solutions for health-related issues. His work is characterized by a commitment to improving the quality of life for individuals affected by Sjogren's syndrome.
Collaborations
Some of Myeong Soo Park's coworkers include Geun Eog Ji and Min Hee Um. Their collaborative efforts contribute to the advancement of research and development in their field.
Conclusion
Myeong Soo Park's contributions to the treatment of Sjogren's syndrome through innovative compositions highlight his role as a significant inventor in the medical field. His work not only addresses a critical health issue but also opens avenues for further research and development.